![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RM Ferris and FL Tang
The ATP-Mg++-dependent uptake of [3H]dopamine and l-[3H]norepinephrine into purified synaptic vesicles of whole rat brain, rat striatum and rat hypothalamus was inhibited 10-fold more effectively by S-(+)- amphetamine as compared to its corresponding (R-(-)-enantiomer. In contrast, S-(+)-deoxypipradrol and its R-(-)-enantiomer were approximately equipotent inhibitors of 3H-amine uptake into these synaptic vesicular preparations. The 1R:2R-methylphenidate was twice as potent as its 1R:2S-enantiomer as an inhibitor of 3H-catecholamine uptake. These data suggest that the receptor sites on the amine pumps present in the membranes of all three vesicular preparations are similar in so far as they are all sensitive to the stereochemical configuration around the alpha-carbon of amphetamine but are not sensitive to the stereochemical configuration around the analogous carbon of deoxypipradrol and methylphenidate. These observations are the reverse of those previously observed for the phenethylamine pumps present in peripheral and central neuronal membranes.
This article has been cited by other articles:
|
|
 |
|
  D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology J Psychopharmacol, January 1, 2007; 21(1): 10 - 41. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Sood, D. L. Barton, and C. L. Loprinzi Use of methylphenidate in patients with cancer American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 35 - 40. [Abstract] [PDF]
|
|
|
|
 |
|
 A. J. Allen, R. M. Kurlan, D. L. Gilbert, B. J. Coffey, S. L. Linder, D. W. Lewis, P. K. Winner, D. W. Dunn, L. S. Dure, F. R. Sallee, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders Neurology, December 27, 2005; 65(12): 1941 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zametkin, J. L. Rapoport, D. L. Murphy, M. Linnoila, F. Karoum, W. Z. Potter, and D. Ismond Treatment of Hyperactive Children With Monoamine Oxidase Inhibitors: II. Plasma and Urinary Monoamine Findings After Treatment Arch Gen Psychiatry, October 1, 1985; 42(10): 969 - 973. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Zametkin, F. Karoum, M. Linnoila, J. L. Rapoport, G. L. Brown, L.-W Chuang, and R. J. Wyatt Stimulants, Urinary Catecholamines, and Indoleamines in Hyperactivity: A Comparison of Methylphenidate and Dextroamphetamine Arch Gen Psychiatry, March 1, 1985; 42(3): 251 - 255. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
